These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31797240)

  • 21. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?
    Ruiz-Nodar JM; Marín F; Roldán V; Valencia J; Manzano-Fernández S; Caballero L; Hurtado JA; Sogorb F; Valdés M; Lip GY
    Circ Cardiovasc Interv; 2012 Aug; 5(4):459-66. PubMed ID: 22787018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
    Mishra A; Singh M; Acker WW; Kamboj S; Sporn D; Stapleton D; Kaluski E
    J Cardiovasc Pharmacol; 2019 Aug; 74(2):82-90. PubMed ID: 31306367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Impact of different antithrombotic therapy strategy on prognosis in coronary heart disease patients combining with atrial fibrillation: a meta analysis].
    Yuan C; Zhong L; Huang RC
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jun; 45(6):526-535. PubMed ID: 28648031
    [No Abstract]   [Full Text] [Related]  

  • 24. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW
    Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of anti-thrombotic regimens in patients with percutaneous coronary intervention requiring oral anticoagulation: A traditional and network meta-analysis.
    Khan SU; Saleem MA; Abdullah A; Ghimire S; Lekkala M; Rahman H; Lone AN; Kaluski E
    Cardiovasc Revasc Med; 2017; 18(7):535-543. PubMed ID: 28457807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review.
    Capodanno D; Huber K; Mehran R; Lip GYH; Faxon DP; Granger CB; Vranckx P; Lopes RD; Montalescot G; Cannon CP; Ten Berg J; Gersh BJ; Bhatt DL; Angiolillo DJ
    J Am Coll Cardiol; 2019 Jul; 74(1):83-99. PubMed ID: 31272556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis.
    Kim IS; Kim HJ; Kim TH; Uhm JS; Joung B; Lee MH; Pak HN
    J Cardiol; 2018 Oct; 72(4):284-291. PubMed ID: 29706404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atrial fibrillation with percutaneous coronary intervention: Navigating the minefield of antithrombotic therapies.
    Bainey KR; Morais J; Zeymer U; Welsh RC
    Atherosclerosis; 2019 Oct; 289():118-125. PubMed ID: 31494384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF.
    Verheugt FWA; Ambrosio G; Atar D; Bassand JP; Camm AJ; Costabel JP; Fitzmaurice DA; Illingworth L; Goldhaber SZ; Goto S; Haas S; Jansky P; Kayani G; Stepinska J; Turpie AGG; van Eickels M; Kakkar AK;
    Am J Med; 2019 Dec; 132(12):1431-1440.e7. PubMed ID: 31306621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries.
    Patti G; Pecen L; Lucerna M; Huber K; Rohla M; Renda G; Siller-Matula J; Schnabel RB; Cemin R; Kirchhof P; De Caterina R
    Int J Cardiol; 2018 Nov; 270():160-166. PubMed ID: 30220376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement.
    Abdul-Jawad Altisent O; Durand E; Muñoz-García AJ; Nombela-Franco L; Cheema A; Kefer J; Gutierrez E; Benítez LM; Amat-Santos IJ; Serra V; Eltchaninoff H; Alnasser SM; Elízaga J; Dager A; García Del Blanco B; Ortas-Nadal Mdel R; Marsal JR; Campelo-Parada F; Regueiro A; Del Trigo M; Dumont E; Puri R; Rodés-Cabau J
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1706-17. PubMed ID: 27539691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antithrombotic and anticoagulant therapy for atrial fibrillation.
    Dzeshka MS; Lip GY
    Cardiol Clin; 2014 Nov; 32(4):585-99. PubMed ID: 25443239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
    Choi HI; Ahn JM; Kang SH; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1075-1085. PubMed ID: 28527773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual versus triple antithrombotic therapy in patients undergoing percutaneous coronary intervention-meta-analysis and meta-regression.
    Agarwal N; Mahmoud AN; Mojadidi MK; Golwala H; Elgendy IY
    Cardiovasc Revasc Med; 2019 Dec; 20(12):1134-1139. PubMed ID: 30862490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN.
    Søndergaard L; Wong YH; Reddy VY; Boersma LVA; Bergmann MW; Doshi S; Kar S; Sievert H; Wehrenberg S; Stein K; Holmes DR
    JACC Cardiovasc Interv; 2019 Jun; 12(11):1055-1063. PubMed ID: 31171282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antithrombotic Therapy in Atrial Fibrillation and Chronic Ischemic Heart Disease].
    Rychkov AY; Khorkova NY
    Kardiologiia; 2019 May; 59(5):80-86. PubMed ID: 31131772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study.
    Yasuda S; Kaikita K; Ogawa H; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K
    Int J Cardiol; 2018 Aug; 265():108-112. PubMed ID: 29764706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of Dual Versus Triple Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention.
    Agarwal N; Jain A; Mahmoud AN; Bishnoi R; Golwala H; Karimi A; Mojadidi MK; Garg J; Gupta T; Patel NK; Wayangankar S; Anderson RD
    Am J Med; 2017 Nov; 130(11):1280-1289. PubMed ID: 28460853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting.
    Rubboli A; Milandri M; Castelvetri C; Cosmi B
    Cardiology; 2005; 104(2):101-6. PubMed ID: 16020950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.